Hsbc Holdings PLC Has $49.58 Million Position in West Pharmaceutical Services, Inc. $WST

Key Points

• HSBC Holdings reduced its West Pharmaceutical Services stake by 11.8% in the second quarter, selling 18,511 shares and retaining 138,384 shares worth approximately $49.58 million. Institutional investors collectively own 93.9% of the company.
• Analyst sentiment remains positive, with one Strong Buy, 11 Buy, and three Hold ratings. West Pharmaceutical Services has a “Moderate Buy” consensus rating and an average price target of $368.08.
• West exceeded quarterly expectations, reporting $2.37 in EPS versus the $2.08 consensus and revenue of $872.3 million, up 13.8% year over year. The company also declared a quarterly dividend of $0.22 per share, yielding approximately 0.3%.

Hsbc Holdings PLC lessened its holdings in shares of West Pharmaceutical Services, Inc. (NYSE:WST - Free Report) by 11.8% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 138,384 shares of the medical instruments supplier's stock after selling 18,511 shares during the period. Hsbc Holdings PLC owned approximately 0.20% of West Pharmaceutical Services worth $49,576,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the business. Elyxium Wealth LLC acquired a new position in shares of West Pharmaceutical Services during the fourth quarter worth approximately $25,000. CYBER HORNET ETFs LLC bought a new position in West Pharmaceutical Services during the second quarter worth $25,000. Cornerstone Planning Group LLC increased its position in West Pharmaceutical Services by 90.9% during the first quarter. Cornerstone Planning Group LLC now owns 105 shares of the medical instruments supplier's stock worth $26,000 after acquiring an additional 50 shares during the period. Bayban acquired a new position in West Pharmaceutical Services during the 4th quarter valued at $27,000. Finally, Avalon Trust Co bought a new stake in West Pharmaceutical Services in the 2nd quarter valued at $28,000. Institutional investors own 93.90% of the company's stock.

Analyst Upgrades and Downgrades

WST has been the topic of a number of recent research reports. TD Cowen reissued a "buy" rating on shares of West Pharmaceutical Services in a research report on Wednesday, July 15th. Citigroup upped their price target on West Pharmaceutical Services from $400.00 to $412.00 and gave the company a "buy" rating in a report on Monday, August 3rd. BNP Paribas Exane began coverage on West Pharmaceutical Services in a research report on Monday, July 13th. They issued an "outperform" rating and a $447.00 price objective for the company. Morgan Stanley lifted their price objective on West Pharmaceutical Services from $325.00 to $365.00 and gave the stock an "equal weight" rating in a report on Thursday, July 9th. Finally, KeyCorp upped their target price on West Pharmaceutical Services from $350.00 to $390.00 and gave the company an "overweight" rating in a research note on Thursday, July 2nd. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $368.08.

West Pharmaceutical Services Trading Down 0.0%

WST stock opened at $339.90 on Tuesday. West Pharmaceutical Services, Inc. has a 1-year low of $223.83 and a 1-year high of $386.00. The company has a current ratio of 2.82, a quick ratio of 2.12 and a debt-to-equity ratio of 0.07. The business's 50 day moving average is $350.25 and its 200-day moving average is $308.00. The firm has a market cap of $23.92 billion, a P/E ratio of 43.52, a P/E/G ratio of 2.38 and a beta of 1.14.

West Pharmaceutical Services (NYSE:WST - Get Free Report) last announced its quarterly earnings results on Thursday, July 23rd. The medical instruments supplier reported $2.37 EPS for the quarter, beating the consensus estimate of $2.08 by $0.29. West Pharmaceutical Services had a return on equity of 20.11% and a net margin of 16.98%.The business had revenue of $872.30 million for the quarter, compared to analyst estimates of $839.98 million. During the same quarter in the previous year, the firm earned $1.84 EPS. West Pharmaceutical Services's quarterly revenue was up 13.8% on a year-over-year basis. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. Equities analysts anticipate that West Pharmaceutical Services, Inc. will post 8.93 earnings per share for the current fiscal year.

West Pharmaceutical Services Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, August 5th. Stockholders of record on Wednesday, July 29th were issued a $0.22 dividend. The ex-dividend date of this dividend was Wednesday, July 29th. This represents a $0.88 annualized dividend and a dividend yield of 0.3%. West Pharmaceutical Services's dividend payout ratio is presently 11.27%.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.